Biocon Q2FY26 Operating Revenue Up 20% to ₹4,296 Cr
Biocon's Q2FY26 operating revenue rose 20% to ₹4,296 crore. EBITDA increased 29% to ₹928 crore, and PBT surged 153% to ₹183 crore. An earnings call is scheduled for 12th November 2025.
The strong financial results, coupled with strategic expansions and debt settlement, indicate a high positive impact on the company's performance and future prospects.
The announcement highlights strong financial performance with significant growth in revenue, EBITDA, and PBT. The company's strategic initiatives and expansions contribute to a positive outlook.
* Biocon Limited announced its Q2FY26 consolidated financial results with operating revenue at ₹4,296 crore, up 20% year-on-year. * EBITDA grew by 29% to ₹928 crore, and PBT (before exceptional items) surged 153% to ₹183 crore. * Biosimilars revenue increased by 25% to ₹2,721 crore, Generics grew by 24% to ₹774 crore, and CRDMO (Syngene) grew by 2% to ₹911 crore. * The company inaugurated its first OSD manufacturing facility in the U.S. * Biocon has strengthened its balance sheet by settling its structured debt obligations. * An earnings call is scheduled for 12th November 2025 at 9:00 AM IST. * Kiran Mazumdar-Shaw, Chairperson, Biocon Group, stated that the company is well-positioned to sustain growth and deliver long-term value. * Siddharth Mittal, CEO & Managing Director, Biocon Limited, mentioned the commencement of filings for Semaglutide (gOzempic) in various markets. * Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, reported a strong performance in Q2 FY26, achieving 25% year-on-year revenue growth. * Peter Bains, CEO & Managing Director, Syngene International Limited, highlighted the building of a GMP bioconjugation suite for Antibody Drug Conjugates (ADCs).
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.